Company news

Eli Lilly and Company news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera

April 27, 2026

Spherix Global Insights Finds Specialty Split in Perceptions of Direct-to-Patient Platforms for Obesity Treatment

April 24, 2026

Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies

April 20, 2026

Lilly confirms date and conference call for first-quarter 2026 financial results announcement

April 16, 2026

ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health

April 16, 2026

Shed Adds Foundayo™ to Its Platform, Expanding Oral GLP-1 Access for Patients Nationwide

April 15, 2026

Vasa Therapeutics Partners with Lilly TuneLab to Power AI/ML-Driven CAMKII Inhibitor Platform

April 14, 2026

Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL

April 13, 2026

Weight Watchers Launches Eli Lilly and Company’s New Oral GLP-1 Foundayo® Available Through LillyDirect

April 9, 2026

Ro offers Eli Lilly's Foundayo™, the newest GLP-1 innovation

April 9, 2026

Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.

April 9, 2026

Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases

April 8, 2026

Ro launches Eli Lilly's KwikPen®, offering patients a more convenient way to take Zepbound®

April 2, 2026

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

April 1, 2026

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

March 31, 2026

Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity

March 28, 2026

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

March 27, 2026

Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes

March 19, 2026

Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis

March 16, 2026

Form Health Joins the Lilly Employer Connect Platform

March 13, 2026

Andel Launches New Direct-to-Employer Medication Platform to Make GLP-1s Affordable for Millions

March 11, 2026

Samsung Biologics Announces Collaboration with Lilly to Establish New Gateway Labs Site in Korea

March 10, 2026

Amazon Pharmacy Expands Access to Eli Lilly’s Zepbound KwikPen for Weight Management

March 9, 2026

15 Top Press Releases from February

March 6, 2026

Third Annual Bio-IT World Venture, Innovation & Partnering Conference Returns to Boston May 19

March 5, 2026

Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients

March 5, 2026

DIA 2026 Global Annual Meeting Reimagines the World's Leading Life Sciences Forum

March 4, 2026

Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata

February 27, 2026

Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet

February 26, 2026

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen

February 23, 2026

Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)

February 19, 2026

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight

February 18, 2026

Lilly to participate in TD Cowen's 46th Annual Health Care Conference

February 16, 2026

USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company

February 16, 2026

Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer

February 16, 2026

Lilly to acquire Orna Therapeutics to advance cell therapies

February 9, 2026

Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology

February 8, 2026

Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

February 4, 2026

Zonsen PepLib Biotech Enters Global R&D Collaboration and License Agreement with Lilly

February 3, 2026

Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility

January 30, 2026

Repertoire® Immune Medicines Announces Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases

January 29, 2026

Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss

January 28, 2026

Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement

January 21, 2026

Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

January 20, 2026

Ontario Pioneers Access to Treatment for Severe Alopecia Areata with Lilly's Olumiant®

January 14, 2026

NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI

January 12, 2026

Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain Inhibitors

January 12, 2026

Chai Discovery Announces Collaboration with Eli Lilly and Company to Accelerate Biologics Discovery

January 9, 2026

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight

January 8, 2026

Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases

January 7, 2026

← Newer news releases · Older news releases →

Calls

The 5 newest of 32 calls. Every call is listed under its year.

Decks

The 5 newest of 32 decks. Every deck is listed under its year.